23andMe Holding Co.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- 23andMe Holding Co. (ME) operates as a direct-to-consumer genetic testing company, offering saliva-based DNA kits that provide personalized reports on ancestry composition across more than 4,500 regions; health predispositions including genetic health risks, carrier status for inherited conditions, wellness traits, and pharmacogenetics for medications such as simvastatin, citalopram, clopidogrel, and others; and premium subscription services like 23andMe+ Premium for over 100 genetic insights and action tools, and 23andMe+ Total Health incorporating next-generation DNA analyses, exome sequencing, blood testing, and longevity guidance. Founded in 2006 and headquartered in Sunnyvale, California, the company serves consumer markets in the United States, United Kingdom, Canada, and select international regions through its online platform, with historical operations also including the now-phased-out Lemonaid Health telemedicine subsidiary. In recent developments, 23andMe filed for voluntary Chapter 11 bankruptcy in March 2025, completed the sale of substantially all assets to TTAM Research Institute, a nonprofit public benefit corporation, in July 2025 for approximately $305 million, and continues direct-to-consumer services under the new ownership while launching initiatives such as high-resolution African genetic groups and a lung cancer genetics study.
23andMe bankruptcy under congressional investigation for customer data
US House committee seeks testimony from 23andMe co-founder after bankruptcy
23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors
Gulp Data Estimates 23andMe's Data Assets to Be Worth $289 Million Amid Bankruptcy Concerns
What's next for 23andMe and all that DNA data?
US regulators tell 23andMe to protect genetic data
FTC concerned about privacy protections in 23andMe bankruptcy
What users need to know about privacy and data after 23andMe's bankruptcy filing
23andMe bankruptcy: With America's DNA put on sale, market panic gets a new form of testing
23andMe's failure shows how risky it can be to invest in a SPAC
Here's how to delete your genetic data from 23andMe
23andMe wants to sell its most valuable asset. Will your DNA data be safe?
With 23andMe filing for bankruptcy, what happens to consumers' genetic data?
23andMe shares jump as US judge allows sale of customer data
23andMe filed for bankruptcy. Here's why you should be worried about your privacy
23andMe goes bankrupt, will now auction off DNA data
23andMe cofounder says company 'lost its way' without 'proper governance'
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
23andMe co-founder lashes out at CEO Wojcicki after bankruptcy filing, says board lacked oversight
23andMe Customers Can Use DeleteMe to Remove Their Data Amid Bankruptcy Concerns